← Leaderboards
Neil Alan Shneider
Winifred Masterson Burke Med Res Inst
$26,772,582
Attributed
$74,176,537
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $28.7M · FY2010–25$50M$37.5M$25M$12.5M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$72,926,537 · 8
ATSDR$1,250,000 · 1
By mechanism
OT2$51,203,440 · 1
U01$9,796,602 · 1
R01$8,967,963 · 4
RF1$3,213,011 · 1
R56$556,796 · 1
R21$438,725 · 1
Top collaborators
- Yutaka Yoshida5 shared
- Robert P Bowser3 shared
- Matthew Harms3 shared
- Brent T Harris3 shared
- Hemali Phatnani3 shared
- Frank A Provenzano3 shared
- Diane Berengere Re3 shared
- Wassim Elyaman1 shared
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoAmyotrophic Lateral SclerosisGenesPhenotypeMutationMotor NeuronsPatternNeuronsAnimal ModelMutant Strains MiceMotorMolecularPathologyNeurodegenerative DisordersMouse ModelSpinal CordMotor Neuron DiseaseNovel TherapeuticsGeneticMutantSeriesLinkIn VitroAlleles
Grant awards (26)
Access for All in ALS (ALL ALS) West Clinical Coordinating Center$20,235,572
OT2 · FY2025 · NS
Silence ALS: A Platform for the Discovery and Development of Antisense Therapeutics for Patients with Ultra-Rare Forms of ALS$4,636,637
U01 · FY2025 · NS · contact PI
Characterization of Antigen-Specific Immune Response in ALS$3,213,011
RF1 · FY2025 · NS
Corticospinal Neuron Dysfunction and Degeneration in ALS: Testing the Role of Corticomotor Connectivity in Motor Neuron Disease$652,030
R01 · FY2025 · NS
Access for All in ALS (ALL ALS) West Clinical Coordinating Center$14,234,367
OT2 · FY2024 · NS
Silence ALS: A Platform for the Discovery and Development of Antisense Therapeutics for Patients with Ultra-Rare Forms of ALS$5,159,965
U01 · FY2024 · NS · contact PI
Corticospinal Neuron Dysfunction and Degeneration in ALS: Testing the Role of Corticomotor Connectivity in Motor Neuron Disease$645,302
R01 · FY2024 · NS
Access for All in ALS (ALL ALS) West Clinical Coordinating Center$16,733,501
OT2 · FY2023 · NS
Corticospinal neuron dysfunction and degeneration in ALS: testing the role of corticomotor connectivity in motor neuron disease$681,914
R01 · FY2023 · NS
Corticospinal neuron dysfunction and degeneration in ALS: testing the role of corticomotor connectivity in motor neuron disease$693,379
R01 · FY2022 · NS
Mechanisms of FUS Toxicity in Animal and Cellular Models of ALS/FTD.$648,000
R01 · FY2022 · NS · contact PI
Corticospinal neuron dysfunction and degeneration in ALS: testing the role of corticomotor connectivity in motor neuron disease$726,701
R01 · FY2021 · NS
Mechanisms of FUS Toxicity in Animal and Cellular Models of ALS/FTD.$648,000
R01 · FY2021 · NS · contact PI
Mechanisms of FUS Toxicity in Animal and Cellular Models of ALS/FTD.$648,000
R01 · FY2020 · NS · contact PI
Mechanisms of FUS Toxicity in Animal and Cellular Models of ALS/FTD.$648,000
R01 · FY2019 · NS · contact PI
Novel extracellular vesicle and molecular biomarkers of environmental exposure and disease progression in ALS$500,000
R01 · FY2019 · TS · contact PI
Novel extracellular vesicle and molecular biomarkers of environmental exposure and disease progression in ALS$250,000
R01 · FY2019 · TS · contact PI
Novel extracellular vesicle and molecular biomarkers of environmental exposure and disease progression in ALS$500,000
R01 · FY2018 · TS · contact PI
FUS Gain-of-Function Mechanisms in Animal and Cellular Models of ALS$556,796
R56 · FY2017 · NS · contact PI
FUS/TLS GAIN AND LOSS OF FUNCTION IN ALS: ANIMAL AND CELLULAR MODELS OF DISEASE$350,000
R01 · FY2015 · NS · contact PI
FUS/TLS GAIN AND LOSS OF FUNCTION IN ALS: ANIMAL AND CELLULAR MODELS OF DISEASE$346,499
R01 · FY2014 · NS · contact PI
FUS/TLS GAIN AND LOSS OF FUNCTION IN ALS: ANIMAL AND CELLULAR MODELS OF DISEASE$337,750
R01 · FY2013 · NS · contact PI
FUS/TLS GAIN AND LOSS OF FUNCTION IN ALS: ANIMAL AND CELLULAR MODELS OF DISEASE$350,000
R01 · FY2012 · NS · contact PI
FUS/TLS GAIN AND LOSS OF FUNCTION IN ALS: ANIMAL AND CELLULAR MODELS OF DISEASE$342,388
R01 · FY2011 · NS · contact PI
Molecular profiling of gamma motor neuron development$197,225
R21 · FY2011 · NS · contact PI
Molecular profiling of gamma motor neuron development$241,500
R21 · FY2010 · NS · contact PI